CTRI/2021/10/037351招募中3 期
A multicenter, randomized, double-blind, parallel group, placebo-controlled studyto evaluate the efficacy and safety of iptacopan (LNP023) in complement 3glomerulopathy - APPEAR-C3G
ovartis Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosis of C3G as confirmed by renal biopsy within 12 months prior to enrollment (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available, confirmation may be obtained using tissue from the Day -45 biopsy for local assessment.
- •Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 90 days. The doses of other antiproteinuric medications including mycophenolic acids, corticosteroids and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization.
- •Reduced serum C3 (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening.
- •UPCR >= 1.0 g/g sampled from the first morning void urine sample at Day -75 and Day -15.
- •Estimated GFR (using the CKD-EPI formula) or measured GFR >= 30 ml/min/1.73m2 at screening and Day -15.
- •Vaccination against Neisseria meningitidis infection prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
- •If not previously vaccinated, or if a booster is required, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
排除标准
- •Participants who have received any cell or organ transplantation, including kidney transplantation.
- •Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months) with renal biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli.
- •Renal biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%.
- •Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.
- •Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever >= 38°C (100.4°F) within 7 days prior to study treatment administration.
- •A history of recurrent invasive infections caused by encapsulated organisms, e.g., meningococcus or pneumococcus.
- •The use of inhibitors of complement factors (e.g., Factor B, Factor D, C3 inhibitors, anti Complement 5 (C5) antibodies, C5a receptor antagonists) within 6 months prior to the Screening visit.
- •The use of immunosuppressants (except mycophenolic acids), cyclophosphamide or systemic corticosteroids at a dose >7.5 mg/day (or equivalent for a similar medication) within 90 days of study drug administration.
研究者
相似试验
已完成
2 期
A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis2024-511706-23-00Boehringer Ingelheim International GmbH31
进行中（未招募）
1 期
Efficacy and safety study of Benralizumab to reduce OCS use in patients with uncontrolled asthma on high dose inhaled corticosteroid plus LABA and chronic OCS therapyAsthmaEUCTR2013-002523-42-ESAstraZeneca AB120
招募中
3 期
Study of efficacy and safety of iptacopan in participants with IC-MPGJPRN-jRCT2031230365Hirano Takamitsu68
进行中（未招募）
不适用
Comparison of two ways of LCZ696 titration in heart failure patientsChronic heart failureEUCTR2013-001835-33-FIovartis Pharma services AG480
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of LCZ969 in heart failure patients with preserved ejection fraction.EUCTR2013-001747-31-ATovartis Pharma Services AG4,600